Anti-Cancer

Lorlatinib (PIVIKTO) Tablet

$3,600.00

Lorlatinib Pivikto 50/150/200 MG Tablet is a cutting-edge medication utilized in the treatment of certain types of advanced or metastatic non-small cell lung cancer (NSCLC). It contains lorlatinib as its active ingredient, a potent inhibitor of multiple receptor tyrosine kinases, including ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1), which are often mutated in NSCLC.

Strength	Choose an option50mg150mg200mg
	Clear

Quantity

Lorlatinib (PIVIKTO) Tablet quantity

Add to cart

Sku:

N/A

Tag:

Lorlatinib PIVIKTO

Description

Lorlatinib Pivikto 50/150/200 MG Tablet is a cutting-edge medication utilized in the treatment of certain types of advanced or metastatic non-small cell lung cancer (NSCLC). It contains lorlatinib as its active ingredient, a potent inhibitor of multiple receptor tyrosine kinases, including ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1), which are often mutated in NSCLC.

Key Features:

• Multi-Receptor Tyrosine Kinase Inhibitor: Lorlatinib acts as a potent inhibitor of several receptor tyrosine kinases, including ALK and ROS1, which play crucial roles in the proliferation and survival of cancer cells. By blocking these pathways, lorlatinib effectively suppresses tumor growth and progression in NSCLC.
• Treatment of Advanced NSCLC: Lorlatinib Pivikto 50/150/200 MG Tablet is indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on previous ALK-targeted therapies, as well as for the treatment of metastatic NSCLC harboring ROS1 rearrangements. It offers a valuable treatment option for patients with these specific molecular subtypes of NSCLC.
• Oral Administration: Lorlatinib Pivikto 50/150/200 MG Tablet is administered orally, typically once daily with or without food. The convenient dosing regimen enhances patient compliance and adherence to treatment.
• Efficacy: Clinical trials have demonstrated the efficacy of lorlatinib in prolonging progression-free survival and overall survival in patients with ALK-positive or ROS1-positive metastatic NSCLC who have progressed on prior targeted therapies. It has shown superiority over standard treatments, offering new hope for patients with advanced NSCLC.
• Safety Profile: Lorlatinib has a manageable safety profile, with common side effects including fatigue, edema, cognitive effects, gastrointestinal upset, and elevated cholesterol levels. Patients should be closely monitored for adverse reactions, and dose adjustments may be necessary to manage side effects effectively.
• Patient Education: Patients prescribed Lorlatinib Pivikto 50/150/200 MG Tablet should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. This empowers patients to actively participate in their healthcare management and optimize therapeutic outcomes.
• Consultation with Healthcare Provider: Treatment with Lorlatinib Pivikto 50/150/200 MG Tablet should be initiated and monitored by a qualified oncologist

Additional information